Aegerion Pharmaceuticals, Inc. Announces Key Business and Financial Objectives for 2013 as the Company Prepares for U.S. Launch of JUXTAPID™ (lomitapide) Capsules

Published: Jan 07, 2013

CAMBRIDGE, Mass., Jan. 7, 2013 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative, life-altering therapies for patients with debilitating, often fatal, rare diseases, today announced its business objectives for 2013 in conjunction with the 31st Annual J.P. Morgan Healthcare Conference in San Francisco. Marc Beer, President and Chief Executive Officer, will discuss these objectives as part of a live presentation which will be available on Aegerion's website,, on Tuesday, January 8 at 2:00 p.m. PST (5:00 p.m. EST).

Back to news